NSABP MEMBER--MICHIGAN STATE UNIVERSITY

这项研究计划是原发性乳腺癌治疗的一部分。 组- NSABP。 NSABP的主要目标是提高无病 原发性可手术乳腺癌患者的生存率和总生存率， 结肠直肠癌（参见NSABP总部赠款申请， 方案原理和总体科学成就）。 密歇根州立 大学自1976年以来一直是NSABP的成员。 头十 多年来，卫星，校园在密歇根州，形成了一个强大的 在主校区的核心联盟。 目前，我们 正在治疗和随访953名长期服用NSABP佐剂的患者， 协议. 我们预计将增加到160例（30%）患者， 这将大大增加随访患者的数量 在接下来的五年里。 五名接受临床培训的新肿瘤学家 试验加入了我们的社区校园。 他们将为 增加应计费用。 我们的推广计划是一个主要的 在过去的几年里，NSABP的临床试验。 除了我们努力增加NSABP协议的患者外，我们的成员 作为主席积极参加小组的科学活动 乳腺癌诊断和治疗生物制品委员会的成员， 结肠委员会，并组织和计划小组科学计划。 的 PI积极参与试点研究的设计。 具有 完善的实验室，配备HPLC、GLC和质谱仪 仪器，我们的机构将提供给该集团额外的研究 与药物和激素代谢物有关。 我们已经并将继续 积极参加小组会议。 PI一直在 在过去五年中， 护士委员会的护士 我们 为小组的审计计划做出贡献， 审计团队 三位医生参加了最近出版的手稿 并向ASCO会议提交摘要。 我们打算增加这一点 活动 PI积极参与了许多NCI现场访问 和同行审查委员会。 我们的机构有一个特殊的计划，以促进和监测应计的 少数民族参与NSABP试验。 我们有一个独特的组织， 基于学术界的NSABP试验的累积和执行 财团（社区校园）和PI承担所有责任 与小组工作有关的活动。

This research proposal is a part of the Primary Breast Cancer Therapy Group - NSABP. The main objective of the NSABP is to improve disease-free survival and overall survival in patients with primary operable breast and colo-rectal cancer (See the NSABP Headquarters Grant application for protocol rationale and overall scientific achievements). Michigan State University has been a member of NSABP since 1976. During the first ten years, the satellites, campuses in the state of Michigan, formed a strong consortium with the nucleus at the main campus. At the present time, we are treating and following 953 patients on long-term NSABP adjuvant protocols. We expect to increase our accrual to 160 (30%) patients per year which will increase substantially the number of follow-up patients during the next five years. Five new oncologists trained in clinical trials joined our community campuses. They will contribute to the increase of the accrual. Our outreach program has been a major contributor to NSABP clinical trials during the last years. Besides our efforts to accrue patients to NSABP protocols, our members participated actively in the scientific activities of the group as chair of the Committee of Biologics in Diagnosis and Treatment of Breast Cancer, Colon Committee, and organized and planned group scientific programs. The PI participates actively in the design of the pilot studies. Having a well developed laboratory equipped with HPLC, GLC and Mass Spectroscopy apparatuses, our institution will offer to the group additional studies related to drug and hormone metabolites. We have and will continue to participate actively in the group meetings. The PI has been on the executive committee of the group for the last five years and one of the nurses on the Nursing Committee for the last six years. We are contributing to the Audit Program of the group with two nurses assigned to auditing teams. Three physicians have participated in recent publications of manuscripts and abstracts presented to ASCO meetings. We intend to increase this activity. The PI has actively participated in numerous NCI site visits and peer review committees. Our institution has a special program to foster and monitor accrual of ethnic minorities to NSABP trials. We have a unique organization for accrual and execution of NSABP trials based on academic community consortium (community campuses) and the PI assumes responsibility for all activities related to the group efforts.